Background Intensive antiplatelet therapy with three agents might be more effective than guideline treatment for preventing recurrent events in patients with acute cerebral ischaemia. We aimed to compare the safety and efficacy of intensive antiplatelet therapy (combined aspirin, clopidogrel, and dipyridamole) with that of guideline-based antiplatelet therapy.
Introduction
The risk of recurrence after ischaemic stroke and transient ischaemic attack (TIA) is highest immediately after the event and declines over the following weeks. 1 Although aspirin reduces the risk of early recurrence, 2,3 dual antiplatelet therapy might be more effective, with the choice of antiplatelets less important than the use of two agents rather than one (at least when considering drugs with different modes of action such as aspirin, clopidogrel, and dipyridamole). 4 Subsequently, the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial 5,6 found that combined aspirin and clopidogrel was superior to aspirin alone in preventing recurrence by 90 days in Chinese patients with minor ischaemic stroke or TIA when randomly assigned within 24 h of onset.
If dual therapy is superior to monotherapy for acute secondary prophylaxis, then intensive short-term treatment with three antiplatelet agents might be better still, providing the absolute risk of recurrence is high, there is a beneficial reduction in recurrence with treat ment, and the risk of bleeding on treatment does not become excessive. In proof-of-mechanism and proof-of -concept studies, triple therapy was more effective than single or
